key: cord-0850236-z2be45g1
authors: Piantoni, Silvia; Salada, Luisa; Colombo, Enrico; Mendeni, Monia; Damiolini, Ezio; Gatta, Diego; Richini, Donata; Furloni, Roberto; Airò, Paolo; Scarsi, Mirko
title: Reports of three long‐term lung disease following SARS‐CoV‐2 infection
date: 2021-02-09
journal: J Med Virol
DOI: 10.1002/jmv.26831
sha: a66877b2b8440d2b8b25252eec114b43340b8773
doc_id: 850236
cord_uid: z2be45g1

The SARS-CoV-2-pneumonia is a potentially life-threatening disease, that can lead to a high mortality rate [1]. This article is protected by copyright. All rights reserved.

The SARS-CoV-2-pneumonia is a potentially life-threatening disease, that can lead to a high mortality rate. 1 Nevertheless, most of SARS-CoV-2-cases are characterized by mild symptoms and do not require nor hospitalization nor treatment. The duration and the timing of the treatment approved for the moderate-severe disease (antivirals and dexamethasone) are not yet fully elucidated, and the need for other treatment are yet under investigation. 2 Furthermore, some cases of COVID-19 recurrence or relapse after a short-term symptom free interval have been described, but few data are so far available on long-term clinical outcome and disease progression. 3 We have recently reevaluated, 6 months after Hospital discharge, 99 patients out of a series of 272 consecutively admitted to Esine Hospital for COVID19 pneumonia between March 5th and April 5th, 2020. 4 Considering patients who died in the meanwhile, 5 these represent the 54% of all the evaluable cohort. Notably, 6 months after discharge, 53% of these patients reported persistent dyspnea or cough. At high-resolution computed tomography (HRCT), 22% of patients showed ground glass, 26% parenchymal bands, and 7% both of these abnormalities. Fibrosis (3% honey combing, 4% septal thickening) was observed in 7% of patients. Finally, 3% of them developed a new need for long term oxygen treatment.

To discuss possible clinical scenarios, we report here the experience of three patients with nasopharyngeal swab positive for SARS-CoV-2 and pneumonia, admitted during the first epidemic wave, who, after initial recovery, had a clinical and radiological worsening of the lung disease. Their radiological findings are described in Figure 1 . Patients 1 and 2 were included in our original descriptions of Esine cohorts. 4, 5 The first patient is a 48-year-old healthy man, admitted (16th March) for dyspnea, cough and fever, who developed SARS-CoV-2-pneumonia. He was treated with antivirals (darunavir/ ritonavir), hydroxychloroquine, high-flow oxygen in continuous positive airway pressure (C-PAP) mode. After a quick clinical worsening, the patient was transferred in intensive care unit (ICU) for orotracheal intubation and treated with dexamethasone (20 mg/day for 10 days) and enoxaparin (anticoagulant dose). After 52 days of hospitalization, he was restored from orotracheal intubation and transferred in subintensive unit. For persistent dyspnea, prednisone was started (25 mg/day, slowly tapered to 12.5 mg/day). He was discharged on 3rd July. The symptoms ameliorated till the 31st July, when he was readmitted in ICU for fever and respiratory failure.

Multi-Resistant-Staphylococcus-Aureus (MRSA) was found in bronchoalveolar lavage (BAL) and antibiotic treatment was administered. Six months after the initial diagnosis, New York Heart Association (NYHA) Class II dyspnoea persisted with worsening of radiological findings. For nocturnal desaturation, C-PAP was prescribed, together with prednisone (7.5 mg/day). performed within all the specimens tested, BAL fluid was proposed as the best one for COVID-19 diagnosis. 6 However, a high concordance between upper respiratory tract swabs and BAL was further observed in two different multicenter Italian studies. 6, 7 Although in our patients, real-time PCR on BAL was not performed, we remark that nasopharyngeal swabs were long-term continuously negative for SARS-CoV-2, suggesting that reinfection was unlike.

Second, there might be a role for immune system in the maintenance of a chronic phase of the pulmonary disease, as observed in connective tissue diseases-related-and some other idiopathic interstitial lung diseases (ILD) characterized by chronic progression. 8 The worsening of ILD after COVID-19 here described might be similar to the progressive fibrosing clinical phenotype observed in many forms of ILD after phases of acute exacerbations. 8 Short-term steroid treatment was followed by disease progression in Patients 1 and 2. In some other ILD, corticosteroids and/or other immunosuppressive treatment showed some benefit in preventing lung fibrosis progression. 8 Nevertheless, chronic use of corticosteroids may be associated to serious infections (Patient 1). 9 Interestingly, the MRSA coinfection in Patient 1 might be a possible trigger for the polyclonal activation of immune system by the superantigens complex, explaining the reactivation of inflammatory process initially induced by SARS-CoV-2. The paradoxical use of immunosuppressive treatment for an infective disease was suggested by different studies, performed in the first pandemic spread, without relevant side effects. 10 Notably, coinfections appeared more likely related to corticosteroids treatment than to other immunesuppressant agents. 9 The final point of discussion is whether to treat or not paucisymptomatic patients despite the fact that the guidelines do not indicate any treatment in these patients. 2 However, in some cases, as in Patient 3, lung damage might progress, raising the doubt that a more aggressive strategy could be useful also in these subsets of patients. From this point of view, a prompt and a well tolerable treatment should be provided at the COVID-19 diagnosis. Although based on a retrospective study including just nine patients, the successful use of colchicine at the beginning of the disease in the setting of community healthcare patients might an example of a possible approach. 11 Other similar approach with antiinflammatory drugs was described in literature during the pandemic. Antimalarials, initially described as potential prophylaxis or treatment for COVID-19, were not confirmed to be efficacious in reducing mortality in comparison with the SoC in randomized trials. 12 N-acetylcysteine, a precursor of reduced glutathione, and baricitinib, an orally administered, selective inhibitor of Janus kinase 1 and 2, are under investigation as an add-on therapy in COVID-19 together with antiviral agents. 13, 14 In conclusion, the reported cases illustrate the possible arise of chronic lung damage after COVID-19 pneumonia. The use of numerous off-label treatments in these patients, which was almost inevitable during the dramatic first wave of the pandemic, might represent a limitation in our observation. Moreover, we cannot rule out the possible role of other etiologic factors (similar to MRSA in Patient 1) in the re-exacerbation of pulmonary disease.

F I G U R E 1 Radiological findings of the three patients at the moment of the COVID-19 diagnosis and after 3 (T3) and 6 months (T6) of follow-up. The chest high-resolution computed tomography (HRCT) showed an evolution of pneumonia. Patient 1, T0: presence of 40% ground glass pneumonia, T3: presence of 70% ground glass pneumonia and septal thickening, T6: presence of honey combing; Patient 2, T0: presence of 35% ground glass pneumonia, T3: improving of ground glass and parenchyma bands, T6: presence of 35% ground glass pneumonia; Patient 3, T0: presence of 25% ground glass pneumonia, T3: not available, T6: presence of 20% ground glass pneumonia and parenchymal bands

Risk factors associated with mortality among patients with COVID-19 in intensive care units in

Recurrence or relapse of COVID-19 in older patients: a description of three cases

Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome

Response to: 'Correspondence on "Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome" by Kawada

SARS-CoV-2 detection on bronchoalveolar lavage: an Italian multicenter experience

Limited role for bronchoalveolar lavage to exclude COVID-19 after negative upper respiratory tract swabs: a multicentre study

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

Infection risk and safety of corticosteroid use

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia

Treating COVID-19 with colchicine in community healthcare setting

Effect of hydroxychloroquine in hospitalized patients with covid-19

Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19

Baricitinib plus remdesivir for hospitalized adults with covid-19